No authoritative reference available. No authoritative reference available. Business Acquisition, Purchase price allocation, Developed product rights. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Shares repurchased under share repurchase program. No authoritative reference available. Amortization of acquired intangible assets. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Business acquisition, purchase price allocation; in process research and development. No authoritative reference available. No authoritative reference available. No authoritative reference available. Business acquisition contingent value rights issued. No authoritative reference available. No authoritative reference available. No authoritative reference available. The first choice for the employees in calculating the number of RSUs to be granted. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Estimated Fair Value Of in process research and development Product Rights. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Additional payment for each market to the former shareholders upon approval of amrubicin. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Milestone payments. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Maximum upfront and regulatory achievement amount received under the Licenses Agreement. No authoritative reference available. Share Based Compensation Arrangement By Share Based Payments Award Options Exercises In Period Weighted Average Exercise Price. No authoritative reference available. Available-for-sale Securities, Debt Maturities, after One Through Three Years, Amortized Cost. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents the fair value of debt securities which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Contingent consideration other non current liabilities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Comprehensive Income Text Block. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Acquisition related charges - accretion. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Net sales payments termination condition. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Reclassify excess restructuring liability from the acquisition of Pharmion. No authoritative reference available. Milestone payment 2, achieved in time if achieved after specified date. No authoritative reference available. Contingent consideration other current liabilities. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Payment obligations under the agreement termination by the company. No authoritative reference available. Contingent value right per share. No authoritative reference available. Equity Investment in Affiliated Companies. No authoritative reference available. Share based compensation arrangement by share based payment award option vested and expected to vest exercisable weighted average contractual term. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Increase in additional paid-in-capital. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Equity in Losses of Affiliated Companies. No authoritative reference available. No authoritative reference available. No authoritative reference available. Baa rated debt yield. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Excess of investment over share of equity. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Derivative instruments not designated as hedging instruments text block. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Net sales payments. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Revenue Recognition Multiple Element Arrangements. No authoritative reference available. No authoritative reference available. No authoritative reference available. Matured shares tendered in connection with stock option exercises. No authoritative reference available. No authoritative reference available. No authoritative reference available. Milestone payment one. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Net sales payments. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amortization expense associated with certain acquired developed product rights. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amount approved under share repurchase program. No authoritative reference available. Available-for-sale Securities, Debt Maturities, after One Through Three Years, fair value. No authoritative reference available. Net sales payments. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Outstanding Weighted Average Remaining Contractual Term. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Fair Value Liabilities Measured On Recurring Basis Acquisition Related Contingent Consideration. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Investment in affiliated companies excluding excess of investment over share of equity. No authoritative reference available. Condition for redemption of notes in whole or in part in case of change of control. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Maximum percentage royality received from sale of products. No authoritative reference available. No authoritative reference available. No authoritative reference available. Cash, Cash Equivalents and Marketable Securities Available-for-Sale. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities. No authoritative reference available. Intangible Assets, Gross. No authoritative reference available. Adoption of Amendment to ASU No. 2010-06, "Improving Disclosures About Fair Value Measurements". No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Value assigned to product right asset. No authoritative reference available. No authoritative reference available. No authoritative reference available. Stock option transactions text block. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Amortization expense associated with an acceleration of amortization. No authoritative reference available. Amortization expense related to the intangible assets acquired. No authoritative reference available. No authoritative reference available. No authoritative reference available. Milestone payment 2, achieved in time if achieved no later than specified date. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Company may redeem all, but not less than all, of the outstanding CVRs at a cash redemption price equal to the average price per CVR paid for all CVRs by Celgene in prior transactions. No authoritative reference available. Share Based Compensation Arrangement By Share Based Payments Award Options Grants In Period Weighted Average Exercise Price No authoritative reference available. Allocation of pre-paid royalties. No authoritative reference available. Share Based Compensation Arrangement By Share Based Payments Award Options Expirations In Period Weighted Average Exercise Price. No authoritative reference available. Indefinite Lived Intangible Assets Accumulated Amortization. No authoritative reference available. Maximum milestone payments upon achieving certain annual sales levels in United States. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Percentage of Equity interest. No authoritative reference available. Calculation of earnings per share text block. No authoritative reference available. No authoritative reference available. No authoritative reference available. Vested Aggregate Intrinsic Value. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Reduction in royalty payment obligations under termination of agreement. No authoritative reference available. Maximum payment obligations, if the agreement terminated for a material breach. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Vested Weighted Average Remaining Contractual Term Years. No authoritative reference available. No authoritative reference available. No authoritative reference available. Weighted Average Life (Years). No authoritative reference available. Decrease in deferred tax and other assets. No authoritative reference available. Milestone payments received. No authoritative reference available. Risk-adjusted discount rate. No authoritative reference available. No authoritative reference available. No authoritative reference available. Schedule of Inventory. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Fair Value Measurement With Unobservable Input Reconciliation Recurring Basis Liability Value. No authoritative reference available. Warrants, Fair Value Disclosure. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Maximum reduction in future royalties payable by the Company under material breach of agreement. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Eligible To Receive Maximum Development Regulatory Approval And Sales Based Milestones For Each Of Three Discovery Stage. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Share based compensation expense text block. No authoritative reference available. No authoritative reference available. No authoritative reference available. Milestone payments upon regulatory approval of amrubicin in the United States. No authoritative reference available. No authoritative reference available. No authoritative reference available. Eligible To Receive Maximum Development Regulatory Approval And Sales Based . No authoritative reference available. Milestone payments upon receipt of the first approval in the E.U. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Reduction in development milestone payment obligations under termination of agreement. No authoritative reference available. No authoritative reference available. No authoritative reference available. Difference upon generic product units sold and number of generic product units sold plus licensed product units sold. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Minimum percentage royality received from sale of Novartis' FOCALIN XR and RITALIN family of ADHD-related products. No authoritative reference available. No authoritative reference available. No authoritative reference available. Business Acquisition Equity Interest Issued against per share. No authoritative reference available. No authoritative reference available. No authoritative reference available. Restricted Stock Units text block. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Minimum reduction in future royalties payable by the Company under material breach of agreement. No authoritative reference available. Share-Based Compensation Arrangement by Share-Based Payment Award Options Grants in Period Weighted Average Grant Date Fair Value, stock options. No authoritative reference available. No authoritative reference available. No authoritative reference available. Foreign currency forward contracts entered into hedge text block. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Based Payments Award Options Forfeitures In Period Weighted Average Exercise Price. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Available-for-sale Securities, Debt Maturities, after One Through Three Years, Amortized Cost No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Contingent Consideration. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Number of shares of common stock repurchased. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Additional Investment in Series G Convertible Preferred Stock of PTC. No authoritative reference available. No authoritative reference available. No authoritative reference available. The second choice for the employees in calculating the number of RSUs to be granted. No authoritative reference available. No authoritative reference available. No authoritative reference available. Maximum recievable upon achievement of certain milestones. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Increase In Developed And In Process Research And Development Rights Due To Acquisition. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Duration periods of available-for-sale debt securities. No authoritative reference available. Total fair value of shares vested. No authoritative reference available. The third choice for the employees in calculating the number of RSUs to be granted. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Income (loss) before income taxes. No authoritative reference available. Equity in losses of affiliated companies. No authoritative reference available. No authoritative reference available. No authoritative reference available. Share Based Compensation Arrangement By Share Based Payments Award Equity Instruments Other Than Options Forfeited In Period Weighted Average Grant Date Fair Value. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Business Acquisition Cash paid per share. No authoritative reference available. One time milestone payment. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Condition for redemption of notes. No authoritative reference available. Net tax benefit from Tax Examinations. No authoritative reference available. No authoritative reference available. No authoritative reference available. Available For Sale Securities Debt Maturities After Three Through Five Years Fair Value. No authoritative reference available. No authoritative reference available. No authoritative reference available.